Drug Name:
KANUMA Rx
Generic Name and Formulations:
Sebelipase alfa 20mg/10mL; soln for IV infusion after dilution; preservative-free.
Company:
Alexion Pharmaceuticals, Inc.
Therapeutic Use:
Indications for KANUMA:
Treatment of lysosomal acid lipase (LAL) deficiency.
Adults and Children:
<1 month: not established. Give as IV infusion over ≥2hrs; consider further prolonging infusion time for the 3mg/kg dose or if a hypersensitivity reaction occurs. May consider a 1hr infusion for the 1mg/kg dose in those who tolerate the infusion. ≥1 month: 1mg/kg once every other week. If rapidly progressive within first 6 months of life: initially 1mg/kg once weekly; increase to 3mg/kg once weekly if optimal response not achieved. May pre-treat with antipyretics and/or antihistamines.
Warnings/Precautions:
Monitor for hypersensitivity reactions during and after infusion; interrupt or lower infusion rate based on severity. Discontinue immediately and treat if severe hypersensitivity including anaphylaxis occurs. Eggs or egg products allergy. Pregnancy. Nursing mothers.
Pharmacological Class:
Hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme.
Adverse Reactions:
Diarrhea, vomiting, fever, rhinitis, anemia, cough, nasopharyngitis, urticaria, headache, oropharyngeal pain, asthenia, constipation, nausea.
Generic Availability:
NO
How Supplied:
Single-use vials—1
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |